| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We focused on an interaction between drug concentration of antipsychotics and receptor gene polymorphism for prediction of drug response in acute schizophrenia receiving resperidone. While there was a positive correction between drug concentration and improvement of positive symptoms in patients with Ins/Ins genotype in -141Ins/Del of DRD2 gene, an inverse correlation between drug concentration and improvement of negative symptoms in patients with Ins/Del or Del/Del was found. On the other hand, the long-term use of the antipsychotic caused side effects such as obesity and impaired glucose tolerance. There was a higher rate of metabolic syndrome in chronic schizophrenia patients with GSTT1 null. In addition, higher prevalence of metabolic syndrome and hypertension was observed in C allele carrier of CLOCK C3111T gene. It is, thus, reasonable to conclude that a combination of drug concentration and genetic information contributes to personalized medicine in schizophrenia.
|
